206 related articles for article (PubMed ID: 33301031)
1. Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling.
Oberbeck S; Schrader A; Warner K; Jungherz D; Crispatzu G; von Jan J; Chmielewski M; Ianevski A; Diebner HH; Mayer P; Kondo Ados A; Wahnschaffe L; Braun T; Müller TA; Wagle P; Bouska A; Neumann T; Pützer S; Varghese L; Pflug N; Thelen M; Makalowski J; Riet N; Göx HJM; Rappl G; Altmüller J; Kotrová M; Persigehl T; Hopfinger G; Hansmann ML; Schlößer H; Stilgenbauer S; Dürig J; Mougiakakos D; von Bergwelt-Baildon M; Roeder I; Hartmann S; Hallek M; Moriggl R; Brüggemann M; Aittokallio T; Iqbal J; Newrzela S; Abken H; Herling M
Blood; 2020 Dec; 136(24):2786-2802. PubMed ID: 33301031
[TBL] [Abstract][Full Text] [Related]
2. Noncanonical Function of AGO2 Augments T-cell Receptor Signaling in T-cell Prolymphocytic Leukemia.
Braun T; Stachelscheid J; Bley N; Oberbeck S; Otte M; Müller TA; Wahnschaffe L; Glaß M; Ommer K; Franitza M; Gathof B; Altmüller J; Hallek M; Auguin D; Hüttelmaier S; Schrader A; Herling M
Cancer Res; 2022 May; 82(9):1818-1831. PubMed ID: 35259248
[TBL] [Abstract][Full Text] [Related]
3. Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia.
Patil P; Cieslak A; Bernhart SH; Toprak UH; Wagener R; López C; Wiehle L; Bens S; Altmüller J; Franitza M; Scholz I; Jayne S; Ahearne MJ; Scheffold A; Jebaraj BMC; Schneider C; Costa D; Braun T; Schrader A; Campo E; Dyer MJS; Nürnberg P; Dürig J; Johansson P; Böttcher S; Schlesner M; Herling M; Stilgenbauer S; Macintyre E; Siebert R
Genes Chromosomes Cancer; 2020 Apr; 59(4):261-267. PubMed ID: 31677197
[TBL] [Abstract][Full Text] [Related]
4. T-cell prolymphocytic leukemia frequently shows cutaneous involvement and is associated with gains of MYC, loss of ATM, and TCL1A rearrangement.
Hsi AC; Robirds DH; Luo J; Kreisel FH; Frater JL; Nguyen TT
Am J Surg Pathol; 2014 Nov; 38(11):1468-83. PubMed ID: 25310835
[TBL] [Abstract][Full Text] [Related]
5. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia.
Herling M; Patel KA; Teitell MA; Konopleva M; Ravandi F; Kobayashi R; Jones D
Blood; 2008 Jan; 111(1):328-37. PubMed ID: 17890451
[TBL] [Abstract][Full Text] [Related]
6. Micro-RNA networks in T-cell prolymphocytic leukemia reflect T-cell activation and shape DNA damage response and survival pathways.
Braun T; Glass M; Wahnschaffe L; Otte M; Mayer P; Franitza M; Altmüller J; Hallek M; Hüttelmaier S; Schrader A; Herling M
Haematologica; 2022 Jan; 107(1):187-200. PubMed ID: 33543866
[TBL] [Abstract][Full Text] [Related]
7. TCL1A gene involvement in T-cell prolymphocytic leukemia in Japanese patients.
Yokohama A; Saitoh A; Nakahashi H; Mitsui T; Koiso H; Kim Y; Uchiumi H; Saitoh T; Handa H; Jimbo T; Murayama K; Sakura T; Murakami H; Karasawa M; Nojima Y; Tsukamoto N
Int J Hematol; 2012 Jan; 95(1):77-85. PubMed ID: 22189846
[TBL] [Abstract][Full Text] [Related]
8. A case of T cell prolymphocytic leukemia involving blast transformation.
Ichikawa K; Noguchi M; Imai H; Sekiguchi Y; Wakabayashi M; Sawada T; Komatsu N
Int J Hematol; 2011 May; 93(5):667-672. PubMed ID: 21505955
[TBL] [Abstract][Full Text] [Related]
9. Computational gene expression analysis reveals distinct molecular subgroups of T-cell prolymphocytic leukemia.
Mikhaylenko N; Wahnschaffe L; Herling M; Roeder I; Seifert M
PLoS One; 2022; 17(9):e0274463. PubMed ID: 36129940
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia.
Tian S; Zhang H; Zhang P; Kalmbach M; Lee JH; Ordog T; Hampel PJ; Call TG; Witzig TE; Kay NE; Klee EW; Slager SL; Yan H; Ding W
Sci Rep; 2021 Apr; 11(1):8318. PubMed ID: 33859327
[TBL] [Abstract][Full Text] [Related]
11. Advanced Pathogenetic Concepts in T-Cell Prolymphocytic Leukemia and Their Translational Impact.
Braun T; Dechow A; Friedrich G; Seifert M; Stachelscheid J; Herling M
Front Oncol; 2021; 11():775363. PubMed ID: 34869023
[TBL] [Abstract][Full Text] [Related]
12. Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia.
López C; Bergmann AK; Paul U; Murga Penas EM; Nagel I; Betts MJ; Johansson P; Ritgen M; Baumann T; Aymerich M; Jayne S; Russell RB; Campo E; Dyer MJ; Dürig J; Siebert R
Br J Haematol; 2016 Apr; 173(2):265-73. PubMed ID: 26917488
[TBL] [Abstract][Full Text] [Related]
13. T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment.
Gutierrez M; Bladek P; Goksu B; Murga-Zamalloa C; Bixby D; Wilcox R
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569479
[TBL] [Abstract][Full Text] [Related]
14. TCR-induced downregulation of protein tyrosine phosphatase PEST augments secondary T cell responses.
Arimura Y; Vang T; Tautz L; Williams S; Mustelin T
Mol Immunol; 2008 Jun; 45(11):3074-84. PubMed ID: 18457880
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of interleukin 2 signaling and signal transducer and activator of transcription (STAT)5 activation during T cell receptor-mediated feedback inhibition of T cell expansion.
Lee IH; Li WP; Hisert KB; Ivashkiv LB
J Exp Med; 1999 Nov; 190(9):1263-74. PubMed ID: 10544198
[TBL] [Abstract][Full Text] [Related]
16. The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL.
Vasyutina E; Boucas JM; Bloehdorn J; Aszyk C; Crispatzu G; Stiefelhagen M; Breuer A; Mayer P; Lengerke C; Döhner H; Beutner D; Rosenwald A; Stilgenbauer S; Hallek M; Benner A; Herling M
Leukemia; 2015 Oct; 29(10):2003-14. PubMed ID: 25936528
[TBL] [Abstract][Full Text] [Related]
17. GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses.
Sellner L; Brüggemann M; Schlitt M; Knecht H; Herrmann D; Reigl T; Krejci A; Bystry V; Darzentas N; Rieger M; Dietrich S; Luft T; Ho AD; Kneba M; Dreger P
Bone Marrow Transplant; 2017 Apr; 52(4):544-551. PubMed ID: 27941777
[TBL] [Abstract][Full Text] [Related]
18. T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism.
Magro CM; Morrison CD; Heerema N; Porcu P; Sroa N; Deng AC
J Am Acad Dermatol; 2006 Sep; 55(3):467-77. PubMed ID: 16908353
[TBL] [Abstract][Full Text] [Related]
19. TCR gene-engineered T cell: limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity.
Pouw N; Treffers-Westerlaken E; Mondino A; Lamers C; Debets R
Mol Immunol; 2010 Apr; 47(7-8):1411-20. PubMed ID: 20303179
[TBL] [Abstract][Full Text] [Related]
20. Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.
Kawamoto K; Miyoshi H; Yanagida E; Yoshida N; Kiyasu J; Kozai Y; Morikita T; Kato T; Suzushima H; Tamura S; Muta T; Kato K; Eto T; Seki R; Nagafuji K; Sone H; Takizawa J; Seto M; Ohshima K
Eur J Haematol; 2017 May; 98(5):459-466. PubMed ID: 28129454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
